Cargando…
A determination of pan-pathogen antimicrobials?
While antimicrobial drug development has historically mitigated infectious diseases that are known, COVID-19 revealed a dearth of ‘in-advance’ therapeutics suitable for infections by pathogens that have not yet emerged. Such drugs must exhibit a property that is antithetical to the classical paradig...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785259/ https://www.ncbi.nlm.nih.gov/pubmed/35098103 http://dx.doi.org/10.1016/j.medidd.2022.100120 |
_version_ | 1784638923486527488 |
---|---|
author | Prathapan, Praveen |
author_facet | Prathapan, Praveen |
author_sort | Prathapan, Praveen |
collection | PubMed |
description | While antimicrobial drug development has historically mitigated infectious diseases that are known, COVID-19 revealed a dearth of ‘in-advance’ therapeutics suitable for infections by pathogens that have not yet emerged. Such drugs must exhibit a property that is antithetical to the classical paradigm of antimicrobial development: the ability to treat infections by any pathogen. Characterisation of such ‘pan-pathogen’ antimicrobials requires consolidation of drug repositioning studies, a new and growing field of drug discovery. In this review, a previously-established system for evaluating repositioning studies is used to highlight 4 therapeutics which exhibit pan-pathogen properties, namely azithromycin, ivermectin, niclosamide, and nitazoxanide. Recognition of the pan-pathogen nature of these antimicrobials is the cornerstone of a novel paradigm of antimicrobial development that is not only anticipatory of pandemics and bioterrorist attacks, but cognisant of conserved anti-infective mechanisms within the host-pathogen interactome which are only now beginning to emerge. Ultimately, the discovery of pan-pathogen antimicrobials is concomitantly the discovery of a new class of antivirals, and begets significant implications for pandemic preparedness research in a world after COVID-19. |
format | Online Article Text |
id | pubmed-8785259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87852592022-01-25 A determination of pan-pathogen antimicrobials? Prathapan, Praveen Med Drug Discov Review Article While antimicrobial drug development has historically mitigated infectious diseases that are known, COVID-19 revealed a dearth of ‘in-advance’ therapeutics suitable for infections by pathogens that have not yet emerged. Such drugs must exhibit a property that is antithetical to the classical paradigm of antimicrobial development: the ability to treat infections by any pathogen. Characterisation of such ‘pan-pathogen’ antimicrobials requires consolidation of drug repositioning studies, a new and growing field of drug discovery. In this review, a previously-established system for evaluating repositioning studies is used to highlight 4 therapeutics which exhibit pan-pathogen properties, namely azithromycin, ivermectin, niclosamide, and nitazoxanide. Recognition of the pan-pathogen nature of these antimicrobials is the cornerstone of a novel paradigm of antimicrobial development that is not only anticipatory of pandemics and bioterrorist attacks, but cognisant of conserved anti-infective mechanisms within the host-pathogen interactome which are only now beginning to emerge. Ultimately, the discovery of pan-pathogen antimicrobials is concomitantly the discovery of a new class of antivirals, and begets significant implications for pandemic preparedness research in a world after COVID-19. Published by Elsevier B.V. 2022-06 2022-01-24 /pmc/articles/PMC8785259/ /pubmed/35098103 http://dx.doi.org/10.1016/j.medidd.2022.100120 Text en Crown Copyright © 2022 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Prathapan, Praveen A determination of pan-pathogen antimicrobials? |
title | A determination of pan-pathogen antimicrobials? |
title_full | A determination of pan-pathogen antimicrobials? |
title_fullStr | A determination of pan-pathogen antimicrobials? |
title_full_unstemmed | A determination of pan-pathogen antimicrobials? |
title_short | A determination of pan-pathogen antimicrobials? |
title_sort | determination of pan-pathogen antimicrobials? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785259/ https://www.ncbi.nlm.nih.gov/pubmed/35098103 http://dx.doi.org/10.1016/j.medidd.2022.100120 |
work_keys_str_mv | AT prathapanpraveen adeterminationofpanpathogenantimicrobials AT prathapanpraveen determinationofpanpathogenantimicrobials |